March 6, 2006 (Miami Beach) — A subcutaneous formulation of immunoglobulin replacement therapy ( Vivaglobin) produces results in primary immune deficiency diseases (PIDD) that are similar to ...

Major countries covered in the Subcutaneous Immunoglobulin (SCIg) Market report include Germany, UK ... Common off-label indications treated with intravenous immunoglobulin are Guillain-Barre ...

KYOTO, Japan — Subcutaneous (SC) immunoglobulin offers several benefits compared with intravenous (IV) infusion as maintenance treatment for chronic inflammatory demyelinating polyneuropathy ...

ATLANTA, GA—After 12 months of treatment with a new human 20% subcutaneous immunoglobulin (SCIG 20%), patients with Primary Immunodeficiency Diseases (PIDD) reported improved treatment ...

Misbah S et al (2009) Subcutaneous immunoglobulin: opportunities and outlook. Clinical and Experimental Immunology; 158: Suppl. 1, 51-59. Orange J et al (2011) Use of intravenous immunoglobulin in ...

Market Study on Intravenous Immunoglobulin Industry - Treatment for Immunodeficiency Diseases to comprise 1/5th of Total UsageNew York, Dec. 22, 2022 (GLOBE NEWSWIRE) -- As per a study conducted ...

Osaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHub and HyHub ...

The FDA has granted marketing approval to Hizentra, a 20% immunoglobulin subcutaneous liquid for treating patients with primary immunodeficiency. The product, from CSL Behring, was approved after ...

At that time, he suggested starting IV immunoglobulin infusions (IVIG). I was open to anything that would help me fight these infections that were now affecting my daily life. He informed me that I ...